Salvador  Villalpando

Dr. Salvador Villalpando

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Salud Pública de México
Verified
Journal Article
Open access
TLTeresa Shamah Levy
Teresa Shamah Levy
EGElsa B Gaona-Pineda
Elsa B Gaona-Pineda
LCLucia Cuevas-Nasu
Lucia Cuevas-Nasu
DVDanae Valenzuela
Danae Valenzuela
CMCarmen Morales-Ruán
Carmen Morales-Ruán
Salvador  VillalpandoSalvador Villalpando
Salvador Villalpando
Objetivo. Describir la magnitud del sobrepeso y obesidad (SP+OB) en población mexicana de 5-19 años y su asociación con el consumo de frutas y verduras (F+V) y azúcares añadidos. Material y métodos. Se estimó la prevalencia de SP+OB en una muestra de 15 109 escolares y adolescentes participantes en la Encuesta Nacional de Salud y Nutrición (Ensanut) 2020-2023, de acuerdo con los patrones de crecimiento de la Organización Mundial de la Salud. En una submuestra (n=4 014) se estimó el consumo de azúcar añadido, el porcentaje de energía y el consumo de F+V y se analizó la asociación con SP+OB mediante modelos de regresión logística. Resultados. La prevalencia de SP+OB fue de 36.5% y 40.4% en escolares y adolescentes, respectivamente. La mediana del porcentaje de energía de azúcares fue de 12.6% y del consumo de F+V fue de 200 g/d. La probabilidad de SP+OB disminuyó conforme se incrementó el consumo de F+V en niños con padre o madre con índice de masa corporal normal. La probabilidad de SP+OB incrementó con mayor porcentaje de energía de azúcares añadidos. Conclusiones. El bajo consumo de F+V y el alto consumo de azúcares añadidos incrementan la probabilidad de desarrollar SP+OB. Es necesario implementar medidas que lo contrarresten.

22 February 2024 in Current Tropical Medicine Reports
Verified
Journal Article
Closed access
PDF file
Salvador  VillalpandoSalvador Villalpando
Salvador Villalpando
AHAndrés F. Henao-Martínez
Andrés F. Henao-Martínez
CFCarlos Franco-Paredes
Carlos Franco-Paredes

28 February 2022 in Salud Pública de México
Verified
Journal Article
Open access
PDF file
SBSimón Barquera
Simón Barquera
LVLesly Samara Véjar-Rentería
Lesly Samara Véjar-Rentería
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas
NGNayely Garibay-Nieto
Nayely Garibay-Nieto
EGEduardo García-García
Eduardo García-García
JDJuan A. Rivera Dommarco
Juan A. Rivera Dommarco
La creciente epidemia de obesidad ha sido uno de los retos más importantes de salud pública en México durante los últimos años. Con apoyo de la Federación Mundial de Obesidad, en 2021 formamos un grupo de profesionales para identificar y resumir las acciones prioritarias en las que puede enfocarse nuestro país para hacer frente a esta epidemia. Al proceso de desarrollo y discusión de este grupo se sumaron más de 1 000 profesionales de la salud para retomar recomendaciones de documentos y guías de alto nivel previamente publicados. En conmemoración del Día Mundial de la Obesidad, en este 2022 se presenta esta postura como insumo para el desarrollo de acciones en el ámbito profesional y de los diferentes sectores, en la que se incluyen 10 recomendaciones de acción, desde la perspectiva poblacional hasta la atención individualizada, y se enfatiza en la importancia de la participación social, de las intervenciones integrales con visión centrada en la persona y de la sostenibilidad planetaria, además de mejorar la educación y las campañas de difusión, propiciar un ambiente promotor de entornos activos y blindar de conflictos de interés los esfuerzos de prevención y control. La postura hace un llamado para abordar la obesidad de manera seria, con base en la evidencia científica, oportuna e integral, con enfoque de curso de vida, de forma ética y sensible, y sin perpetuar las barreras del estigma de peso en la sociedad.

1 November 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
Andrés Henao-MartinezAndrés Henao-Martinez
Andrés Henao-Martinez
COChristian Olivo-Freites
Christian Olivo-Freites
NHNelson I. Agudelo Higuita
Nelson I. Agudelo Higuita
CFCarolina Ferraz
Carolina Ferraz
Carlos Franco-ParedesCarlos Franco-Paredes
Carlos Franco-Paredes
ARAnis Rassi
Anis Rassi
: Chagas disease affects approximately 300,000 patients in the United States. We evaluated a multicenter U.S.-based network to obtain clinical characteristics and outcomes of chronic Chagas disease by disease forms. This was a U.S.-based, multicenter, population-based, retrospective cohort study. We queried TriNetX, a global research network, to identify patients with dual-positive IgG serology for Trypanosoma cruzi. We captured outcomes of interest for up to 5 years. We found 429 patients with evidence of dual-positive T. cruzi IgG out of 19,831 patients with an available test result from 31 U.S. medical centers. The positive proportion for those tested was 2.2%, up to 4.6% among Hispanics. We found a prevalence of a positive Chagas serology of 0.02% among Hispanics. Cardiomyopathy risk reached an annual rate of 1.3% during the initial 5 years of follow-up among patients with the indeterminate form. We found no new events for pulmonary embolism, sudden death, or left ventricular aneurysms at 5 years. Annual risks for arrhythmias and stroke for chronic Chagas cardiomyopathy (CCC) were 1.6% and 0.8%, respectively. The yearly mortality and hospitalization rates for CCC were 2.7% and 17.1%, respectively. Only 13 patients had a documented antitrypanosomal therapy course within 6 months after diagnosis. Of those receiving treatment, 10 patients received benznidazole and three nifurtimox. Chagas disease screening in patients from endemic areas living in the United States remains crucial. Chronic Chagas cardiomyopathy carries a considerable disease burden, translating into increased morbidity and mortality and an enlarging medical health service utilization.

3 July 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
Andrés Henao-MartinezAndrés Henao-Martinez
Andrés Henao-Martinez
CFChristian Olivo Freites
Christian Olivo Freites
NHNelson I. Agudelo Higuita
Nelson I. Agudelo Higuita
Luis A. MarcosLuis A. Marcos
Luis A. Marcos
DCDaniel Chastain
Daniel Chastain
Carlos Franco-ParedesCarlos Franco-Paredes
Carlos Franco-Paredes
: Human strongyloidiasis is a potentially life-threatening parasitic disease among immunocompromised hosts. We aim to determine the factors and mortality associated with disseminated strongyloidiasis. We conducted a U.S.-based multicenter retrospective cohort study to determine 90-day clinical outcomes for people diagnosed with Strongyloides infection in the TriNetX patient database. We identified adult patients with the International Classification of Diseases (10th revision, clinical modification) code for Strongyloides infection (B78) or a positive Strongyloides IgG antibody test and captured outcomes at 90 days. We identified 5,434 patients with strongyloidiasis, of whom 48 had disseminated strongyloidiasis for 0.9% prevalence of disseminated disease. Systemic connective tissue disorders, pulmonary eosinophilia, liver cirrhosis, blood disorders (monoclonal gammopathy, aplastic anemia, and lymphoid malignancy), malnutrition, alcohol use disorder, and transplantation status were frequent in patients with disseminated disease. Mortality was significantly higher in people with disseminated disease at 30 days (21%). The 90-day risk of hospitalization, bacteremia, and acute respiratory distress syndrome (ARDS) was higher in those with disseminated infection. People with disseminated strongyloidiasis had a heightened risk of hospitalization, bacteremia, acute respiratory distress syndrome, and mortality. The population at risk for severe strongyloidiasis infection is evolving, reflecting conditions in which glucocorticoids or additional immunosuppressive medications are commonly used for treatment.

23 June 2015 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
FRFabian R. Reimold
Fabian R. Reimold
SBSavithri Balasubramanian
Savithri Balasubramanian
DDDavid B. Doroquez
David B. Doroquez
BSBoris E. Shmukler
Boris E. Shmukler
ZZZsuzsanna Kinga Zsengeller
Zsuzsanna Kinga Zsengeller
SASeth L. Alper
Seth L. Alper
Congenital chloride diarrhea is an autosomal recessive disease caused by mutations in the intestinal lumenal membrane Cl-/HCO3- exchanger, SLC26A3. We report here the novel SLC26A3 mutation G393W in a Mexican child, the first such report in a patient from Central America. SLC26A3 G393W expression in Xenopus oocytes exhibits a mild hypomorphic phenotype, with normal surface expression and moderately reduced anion transport function. However, expression of HA-SLC26A3 in HEK-293 cells reveals intracellular retention and greatly decreased steady-state levels of the mutant polypeptide, in contrast to peripheral membrane expression of the wildtype protein. Whereas wildtype HA-SLC26A3 is apically localized in polarized monolayers of filter-grown MDCK cells and Caco2 cells, mutant HA-SLC26A3 G393W exhibits decreased total polypeptide abundance, with reduced or absent surface expression and sparse punctate (or absent) intracellular distribution. The WT protein is similarly localized in LLCPK1 cells, but the mutant fails to accumulate to detectable levels. We conclude that the chloride-losing diarrhea phenotype associated with homozygous expression of SLC26A3 G393W likely reflects lack of apical surface expression in enterocytes, secondary to combined abnormalities in polypeptide trafficking and stability. Future progress in development of general or target-specific folding chaperonins and correctors may hold promise for pharmacological rescue of this and similar genetic defects in membrane protein targeting.